Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pressure intensifies on UK to increase vCJD testing

This article was originally published in Clinica

Executive Summary

UK spongiform encephalopathy experts have quantified in terms of incidence levels their growing concerns that one or more waves of variant Creutzfeldt-Jakob disease (vCJD) may yet arise as a result of new patterns of genetic susceptibility. But the main implication of the development is the increased urgency of developing a diagnostic to screen for the disease in asymptomatic carriers, given that, instead of the risk of infectivity tailing off, there could be a significant additional proportion of carriers in the population.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT043230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel